Pain and pruritus are the main contributors to AD burden and poor health-related QoL.

Psoriasis patients with pruritis and related sleep distrubances showed a lower quality of life in all domains.

Researchers developed a PRESTO tool using clinical variables to predict PsA risk in PsO patients with reasonable accuracy.

The use of dupilumab in patients with AD did not significantly affect the results of patch tests for allergic contact dermatitis.

Roflumilast showed significant improvement in disease severity in 95% of plaque psoriasis patients by week 8.

Patients who have contracted Covid-19 may have a higher risk of developing psoriasis and other immune-mediated inflammatory diseases.

Colloidal oatmeal 1% is efficacious in treating mild-to-moderate AD in Black children, according to a recent study.

Dr. Ronald B. Vender gives insights into JAK inhibitors and patient aspects of skin diseases at the 2023 EADV Congress in Berlin.